A search of the Clinicaltrials.gov (accessed on 1 April 2021) website showed that the following compounds that block the protein–protein interaction between p53 and MDM2 in CRC or solid cancers, which are not further specified, are currently or have been in phase I/II clinical trials (Table 1): RG7112/RO5045337 [138], RG7388/Idasanutlin [139,140,141,142], RO6839921/RG7775 [143], SAR405838/MI-77031 [144,145], AMG232 [146], MK-8242 [147], CGM097 [148], APG-115 [149,150,151], BI 907828 [152,153], HDM201 [154,155,156,157], and Milademetan/DS-3032b [158]. Here, TP53 is linked to colorectal carcinoma.